Kura Oncology (NASDAQ:KURA) Downgraded to Sell Rating by StockNews.com

by · The Cerbat Gem

StockNews.com cut shares of Kura Oncology (NASDAQ:KURA – Free Report) from a hold rating to a sell rating in a research report released on Wednesday.

KURA has been the subject of several other reports. Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $28.83.

Read Our Latest Stock Analysis on KURA

Kura Oncology Stock Down 0.3 %

NASDAQ:KURA opened at $15.91 on Wednesday. Kura Oncology has a twelve month low of $9.06 and a twelve month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a fifty day simple moving average of $18.28 and a 200-day simple moving average of $19.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Avoro Capital Advisors LLC increased its position in shares of Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Suvretta Capital Management LLC increased its position in Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after buying an additional 583,155 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares during the last quarter. Affinity Asset Advisors LLC raised its stake in Kura Oncology by 281.4% in the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after buying an additional 538,957 shares during the last quarter. Finally, Sofinnova Investments Inc. boosted its holdings in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares in the last quarter.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Further Reading